应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02607 上海医药
已收盘 05-02 16:08:16
11.200
+0.060
+0.54%
最高
11.260
最低
10.900
成交量
201.87万
今开
11.060
昨收
11.140
日振幅
3.23%
总市值
414.77亿
流通市值
102.94亿
总股本
37.03亿
成交额
2,248万
换手率
0.22%
流通股本
9.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
智通AH统计|5月2日
智通财经 · 34分钟前
智通AH统计|5月2日
上海医药(02607.HK):注射用帕瑞昔布钠新增规格获内地批准
阿斯达克财经 · 09:36
上海医药(02607.HK):注射用帕瑞昔布钠新增规格获内地批准
上海医药:终止I010项目等三个研发项目的临床试验及后续开发
证券时报网 · 04-30 18:50
上海医药:终止I010项目等三个研发项目的临床试验及后续开发
上海医药最新公告:注射用帕瑞昔布钠新增规格获得批准文号
证券之星 · 04-30 18:49
上海医药最新公告:注射用帕瑞昔布钠新增规格获得批准文号
上海医药(02607)注射用帕瑞昔布钠新增规格40mg获得批准文号
智通财经 · 04-30 18:47
上海医药(02607)注射用帕瑞昔布钠新增规格40mg获得批准文号
上海医药(02607.HK):注射用帕瑞昔布钠新增规格获得批准文号
格隆汇资讯 · 04-30 18:45
上海医药(02607.HK):注射用帕瑞昔布钠新增规格获得批准文号
上海医药最新公告:终止I010项目、B002项目及B003项目的临床试验及后续开发
证券之星 · 04-30 18:30
上海医药最新公告:终止I010项目、B002项目及B003项目的临床试验及后续开发
上海医药(601607.SH):注射用帕瑞昔布钠新增规格获批
智通财经 · 04-30 18:29
上海医药(601607.SH):注射用帕瑞昔布钠新增规格获批
智通AH统计|4月30日
智通财经 · 04-30 16:15
智通AH统计|4月30日
国金证券:给予上海医药买入评级
证券之星 · 04-30 11:14
国金证券:给予上海医药买入评级
智通AH统计|4月29日
智通财经 · 04-29
智通AH统计|4月29日
信达证券发布上海医药研报,2024Q1医药商业营收增长8%,商业创新业务表现亮眼
每日经济新闻 · 04-28
信达证券发布上海医药研报,2024Q1医药商业营收增长8%,商业创新业务表现亮眼
图解上海医药一季报:第一季度单季净利润同比增1.62%
证券之星 · 04-27
图解上海医药一季报:第一季度单季净利润同比增1.62%
上海医药2024年一季报:业绩稳健增长 创新加速推进
中国财富通 · 04-26
上海医药2024年一季报:业绩稳健增长 创新加速推进
上海医药最新公告:一季度净利润15.42亿元 同比增加1.62%
证券之星 · 04-26
上海医药最新公告:一季度净利润15.42亿元 同比增加1.62%
上海医药(601607.SH):一季度净利润15.42亿元,同比增加1.62%
港股那点事 · 04-26
上海医药(601607.SH):一季度净利润15.42亿元,同比增加1.62%
上海医药(601607.SH)发布一季度业绩,净利润15.42亿元 同比增加1.62%
智通财经 · 04-26
上海医药(601607.SH)发布一季度业绩,净利润15.42亿元 同比增加1.62%
上海医药最新公告:拟发行余额不超150亿元债务融资产品
证券之星 · 04-26
上海医药最新公告:拟发行余额不超150亿元债务融资产品
上海医药(02607)拟申请发行各类短期债务融资产品和中长期债务融资产品
智通财经 · 04-26
上海医药(02607)拟申请发行各类短期债务融资产品和中长期债务融资产品
上海医药(02607)发布一季度业绩 归母净利润15.42亿元 同比增加1.62%
智通财经 · 04-26
上海医药(02607)发布一季度业绩 归母净利润15.42亿元 同比增加1.62%
公司概况
公司名称:
上海医药
所属市场:
SEHK
上市日期:
--
主营业务:
上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外,该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。
发行价格:
--
{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.2,"timestamp":1714637296032,"preClose":11.14,"halted":0,"volume":2018683,"delay":0,"floatShares":919072704,"shares":3703301054,"eps":1.1003646,"marketStatus":"已收盘","marketStatusCode":5,"change":0.06,"latestTime":"05-02 16:08:16","open":11.06,"high":11.26,"low":10.9,"amount":22484767,"amplitude":0.032316,"askPrice":11.26,"askSize":40600,"bidPrice":11.2,"bidSize":52500,"shortable":3,"etf":0,"ttmEps":1.1097671477156368,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714699800000},"adr":0,"listingDate":1305820800000,"adjPreClose":11.14,"dividendRate":0.039539,"openAndCloseTimeList":[[1714613400000,1714622400000],[1714626000000,1714636800000]],"volumeRatio":0.615401,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.92,"timestamp":1714460400000,"preClose":18.06,"halted":0,"volume":10128819,"delay":0,"premium":"-42.18"}},"requestUrl":"/m/hq/s/02607/wiki","defaultTab":"wiki","newsList":[{"id":"2432562854","title":"智通AH统计|5月2日","url":"https://stock-news.laohu8.com/highlight/detail?id=2432562854","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432562854?lang=zh_cn&edition=full","pubTime":"2024-05-02 16:15","pubTimestamp":1714637705,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止5月2日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为988.71%、754.48%、508.17%;招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位,溢价率分别为15.29%、16.32%、21.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116887.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432930446","title":"上海医药(02607.HK):注射用帕瑞昔布钠新增规格获内地批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2432930446","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432930446?lang=zh_cn&edition=full","pubTime":"2024-05-02 09:36","pubTimestamp":1714613760,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 公布,下属全资子公司上药东英(江苏)药业的注射用帕瑞昔布钠收到国家药监局颁发的《药品补充申请批准通知书》,该药品新增规格40mg获得批准。注射用帕瑞昔布钠主要用于手术后疼痛的短期治疗,最早由辉瑞研发,于2002年在欧洲上市。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210429113036647_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346761/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431311051","title":"上海医药:终止I010项目等三个研发项目的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2431311051","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2431311051?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:50","pubTimestamp":1714474232,"startTime":"0","endTime":"0","summary":"【上海医药:终止I010项目等三个研发项目的临床试验及后续开发】上海医药(601607)4月30日晚间公告,公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估,决定终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发。其中,I010项目及B002项目处于I期临床试验阶段,B003项目处于II期临床试验阶段。按照相关会计准则和公司会计政策,上述研发项目的研发投入已全部费用化并计入相应会计期间损益。本次终止临床试验及后续开发事项,不会对公司业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404303065707735.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404303065707735.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431031450","title":"上海医药最新公告:注射用帕瑞昔布钠新增规格获得批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2431031450","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431031450?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:49","pubTimestamp":1714474161,"startTime":"0","endTime":"0","summary":"上海医药公告,公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估,决定终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发。按照相关会计准则和公司会计政策,上述研发项目的研发投入已全部费用化并计入相应会计期间损益。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000045028.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431319035","title":"上海医药(02607)注射用帕瑞昔布钠新增规格40mg获得批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2431319035","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431319035?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:47","pubTimestamp":1714474038,"startTime":"0","endTime":"0","summary":"2023年3月,上药东英就该药品新增40mg规格向国家药监局提出申请并获受理。IQVIA数据库显示,2023年注射用帕瑞昔布钠医院采购金额为人民币2.72亿元。公告称,本次取得药品补充申请批准通知书是在注射用帕瑞昔布钠20mg的基础上新增了40mg规格的产品,能进一步丰富患者的用药选择,有助于扩大该药品的市场份额,提升市场竞争力,将对公司经营产生积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116394.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431194243","title":"上海医药(02607.HK):注射用帕瑞昔布钠新增规格获得批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2431194243","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431194243?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:45","pubTimestamp":1714473929,"startTime":"0","endTime":"0","summary":"格隆汇4月30日丨上海医药(02607.HK)公告,近日,上海医药集团股份有限公司(以下简称“上海医药”或“公司”)下属全资子公司上药东英(江苏)药业有限公司(以下简称“上药东英”)的注射用帕瑞昔布钠(以下简称“该药品”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的《药品补充申请批准通知书》(通知书编号:2024B01860),该药品新增规格40mg获得批准。本次取得药品补充申请批准通知书是在注射用帕瑞昔布钠20mg的基础上新增了40mg规格的产品,能进一步丰富患者的用药选择,有助于扩大该药品的市场份额,提升市场竞争力,将对公司经营产生积极的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301846158b65f2eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301846158b65f2eb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431758316","title":"上海医药最新公告:终止I010项目、B002项目及B003项目的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2431758316","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431758316?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:30","pubTimestamp":1714473002,"startTime":"0","endTime":"0","summary":"上海医药公告,为合理配置研发资源、聚焦优势研发项目,公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估,决定终止I010项目、B002项目以及B003项目三个研发项目的临床试验及后续开发。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000044013.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431316736","title":"上海医药(601607.SH):注射用帕瑞昔布钠新增规格获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431316736","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431316736?lang=zh_cn&edition=full","pubTime":"2024-04-30 18:29","pubTimestamp":1714472959,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药(601607.SH)公告,近日,公司下属全资子公司上药东英(江苏)药业有限公司(“上药东英”)的注射用帕瑞昔布钠(“该药品”)收到国家药品监督管理局(“国家药监局”)颁发的《药品补充申请批准通知书》,该药品新增规格40mg获得批准。据悉,注射用帕瑞昔布钠主要用于手术后疼痛的短期治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116369.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431676853","title":"智通AH统计|4月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=2431676853","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431676853?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:15","pubTimestamp":1714464905,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止4月30日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1073.91%、760.90%、616.97%;招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位,溢价率分别为19.65%、21.39%、21.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116187.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431874323","title":"国金证券:给予上海医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431874323","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431874323?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:14","pubTimestamp":1714446850,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司近期对上海医药进行研究并发布了研究报告《创新药管线渐丰,中药增长,转型提速中》,本报告对上海医药给出买入评级,当前股价为18.04元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有6家机构给出评级,买入评级5家,增持评级1家;过去90天内机构目标均价为22.19。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024171.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431007114","title":"智通AH统计|4月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2431007114","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431007114?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:15","pubTimestamp":1714378504,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止4月29日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1073.91%、771.43%、626.98%;招商银行、紫金矿业、比亚迪股份分列AH溢价率末三位,溢价率分别为19.71%、21.41%、22.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114108.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430081070","title":"信达证券发布上海医药研报,2024Q1医药商业营收增长8%,商业创新业务表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2430081070","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430081070?lang=zh_cn&edition=full","pubTime":"2024-04-28 15:04","pubTimestamp":1714287864,"startTime":"0","endTime":"0","summary":"信达证券04月28日发布研报称,给予上海医药(601607.SH,最新价:17.85元)评级。评级理由主要包括:1)2024Q1医药工业业务短期承压,医药商业业务持续稳健增长;2)“自主研发+并购引进+孵化培育”驱动,2024Q1创新进展再创佳绩。风险提示:应收账款回收不及时,融资利率上行,市场竞争加剧,工业新品上市进度不及预期,集采降价超预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404283062566173.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404283062566173.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293781","title":"图解上海医药一季报:第一季度单季净利润同比增1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293781","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430293781?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:01","pubTimestamp":1714154512,"startTime":"0","endTime":"0","summary":"证券之星消息,上海医药2024年一季报显示,公司主营收入701.53亿元,同比上升5.93%;归母净利润15.42亿元,同比上升1.62%;扣非净利润13.75亿元,同比上升1.3%;负债率62.25%,投资收益1.66亿元,财务费用3.74亿元,毛利率11.44%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700003578.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430748472","title":"上海医药2024年一季报:业绩稳健增长 创新加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2430748472","media":"中国财富通","top":-1,"share":"https://www.laohu8.com/m/news/2430748472?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:56","pubTimestamp":1714136183,"startTime":"0","endTime":"0","summary":"4月27日,上海医药集团股份有限公司发布2024年一季报。报告期内,公司实现营业收入701.53亿元,同比增长5.93%,其中:医药工业实现销售收入69.44亿元;医药商业实现销售收入632.09亿元,同比增长8.19%。报告期内,公司研发投入7.15亿元,同比增加30.78%。报告期内,公司新增2项新药管线。报告期内,公司继续保持进口创新药总代的领先地位,创新药板块销售同比增幅约33%,成功引入4个进口总代品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=n4ZPWI6ZbJE%3D","is_publish_highlight":false,"gpt_icon":0},{"id":"2430922081","title":"上海医药最新公告:一季度净利润15.42亿元 同比增加1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430922081","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430922081?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:12","pubTimestamp":1714129921,"startTime":"0","endTime":"0","summary":"上海医药发布2024年一季度报告,报告期内公司实现营业收入701.53亿元,同比增加5.93%;归属于上市公司股东的净利润15.42亿元,同比增加1.62%;归属于上市公司股东的扣除非经常性损益的净利润13.75亿元,同比增加1.3%;基本每股收益0.42元。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600048040.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430222649","title":"上海医药(601607.SH):一季度净利润15.42亿元,同比增加1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430222649","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2430222649?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:58","pubTimestamp":1714129121,"startTime":"0","endTime":"0","summary":"格隆汇4月26日丨上海医药(601607.SH)发布2024年一季度报告,报告期内公司实现营业收入701.53亿元,同比增加5.93%;归属于上市公司股东的净利润15.42亿元,同比增加1.62%;归属于上市公司股东的扣除非经常性损益的净利润13.75亿元,同比增加1.3%;基本每股收益0.42元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-26/doc-inateiev5905764.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-26/doc-inateiev5905764.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430224733","title":"上海医药(601607.SH)发布一季度业绩,净利润15.42亿元 同比增加1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430224733","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430224733?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:52","pubTimestamp":1714128732,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药(601607.SH)发布2024年一季度报告,报告期内公司实现营业收入701.53亿元,同比增加5.93%;归属于上市公司股东的净利润15.42亿元,同比增加1.62%;归属于上市公司股东的扣除非经常性损益的净利润13.75亿元,同比增加1.3%;基本每股收益0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111957.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430522510","title":"上海医药最新公告:拟发行余额不超150亿元债务融资产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430522510","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430522510?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:47","pubTimestamp":1714124828,"startTime":"0","endTime":"0","summary":"上海医药公告,拟发行余额不超过等值人民币150亿元的各类短期债务融资产品和中长期债务融资产品。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600042119.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430240423","title":"上海医药(02607)拟申请发行各类短期债务融资产品和中长期债务融资产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430240423","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430240423?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:14","pubTimestamp":1714122850,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药(02607)发布公告,公司拟申请发行余额不超过等值人民币150亿元的各类短期债务融资产品和中长期债务融资产品,融资产品类别包括但不限于短期融资券、超短期融资券、短期公司债券、中期票据、中长期公司债券、永续债、类永续债、资产支持票据、绿色债务融资工具、科创票据和其他短期及中长期债务融资产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111643.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430244786","title":"上海医药(02607)发布一季度业绩 归母净利润15.42亿元 同比增加1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430244786","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430244786?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:40","pubTimestamp":1714120840,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海医药(02607)发布2024年第一季度业绩,该集团期内取得营业收入701.53亿元(人民币,下同),同比增加5.93%;归母净利润15.42亿元,同比增加1.62%;基本每股收益0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111520.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.0142},{"period":"3month","weight":0.0091},{"period":"6month","weight":-0.0107},{"period":"1year","weight":-0.2674},{"period":"ytd","weight":-0.0245}],"compareEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":0.0739},{"period":"3month","weight":0.1471},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1071},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药工业、分销与零售业务的中国公司。该公司的产品包括创新药、化学药、中药和罕见病药。该公司的产品主要用于心血管系统、消化道和新陈代谢、全身性抗感染、中枢神经系统、抗肿瘤和免疫调节剂、骨骼肌肉系统和呼吸系统等领域。另外,该公司还提供医药物流和仓储服务。该公司的产品销往中国国内和海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.004801},{"month":2,"riseRate":0.615385,"avgChangeRate":0.022513},{"month":3,"riseRate":0.615385,"avgChangeRate":0.015446},{"month":4,"riseRate":0.538462,"avgChangeRate":0.003329},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010331},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.014458},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.02229},{"month":8,"riseRate":0.461538,"avgChangeRate":0.012296},{"month":9,"riseRate":0.307692,"avgChangeRate":0.002433},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.017861},{"month":11,"riseRate":0.384615,"avgChangeRate":0.027207},{"month":12,"riseRate":0.615385,"avgChangeRate":-0.010293}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}